论文部分内容阅读
目的探讨低分子肝素钙联合辛伐他汀治疗不稳定型心绞痛的临床疗效。方法将60例不稳定型心绞痛患者随机分为两组各30例,两组均给予内科常规治疗,治疗组应用低分子肝素钙联合辛伐他汀治疗,对照组给予普通肝素治疗。观察30d。依据两组患者治疗前后临床表现及心电图改变为标准判断临床疗效及不良反应。结果治疗组总有效率90.0%,所有病例均未出现皮肤黏膜出血等不良反应;对照组总有效率66.7%;16.67%出现皮肤黏膜出血不良反应。治疗组总有效率显著高于对照组(χ2=4.812,P<0.05),皮肤黏膜出血不良反应发生率显著低于对照组(χ2=5.455,P<0.05)。结论在内科常规治疗的基础上应用低分子肝素钙联合辛伐他汀治疗不稳定型心绞痛较单用普通肝素疗效更显著,可防止或减少冠心病患者心血管不良事件的发生。
Objective To investigate the clinical effect of low molecular weight heparin combined with simvastatin in the treatment of unstable angina pectoris. Methods Sixty patients with unstable angina were randomly divided into two groups of 30 patients. Both groups were given routine medical treatment. The patients in the treatment group were treated with low molecular weight heparin and simvastatin. The control group was treated with unfractionated heparin. Observation 30d. According to the two groups of patients before and after treatment of clinical manifestations and ECG changes as the standard to determine the clinical efficacy and adverse reactions. Results The total effective rate was 90.0% in the treatment group. No adverse reactions such as mucocutaneous bleeding occurred in all the cases. The total effective rate was 66.7% in the control group and 16.67% in the mucosal bleeding reaction. The total effective rate of the treatment group was significantly higher than that of the control group (χ2 = 4.812, P <0.05), and the incidence of adverse reactions of skin and mucous membrane bleeding was significantly lower than that of the control group (χ2 = 5.455, P <0.05). Conclusion The application of low molecular weight heparin combined with simvastatin in the treatment of unstable angina pectoris is more effective than single unfractionated heparin on the basis of routine medical treatment, which can prevent or reduce the occurrence of cardiovascular adverse events in patients with coronary heart disease.